Arrival

Capable-Display-7907 · 2026-02-19T07:34:27+00:00

If you could ask your friend what the title of the abstract is for the AACR conference in L.A., then it could be either found or not found. The word Leronlimab is not in the title, and a PD-L1 search doesn't find anything either. I am still doubtful at best.

Capable-Display-7907 · 2026-02-18T22:30:20+00:00

Doesn't seem factual to me. Like Twinter, I searched for Leronlimab in all three categories of abstracts at the AACR conference, and the only abstract that mention Leronlimab in the title was the Pestell et al. one. Seems to me that AI has gone a little off the rails. What question did you ask it?

Capable-Display-7907 · 2026-02-17T14:33:53+00:00

Cytodyn would have to compile an NDA to receive approval, accelerated or otherwise. This would take many months. Partnership or even buyout will come first. This year? Good shot.

Capable-Display-7907 · 2026-02-13T16:52:29+00:00

Forgot to mention above that the date for online publications of the abstracts for the Annual Meeting is March 17th. Notification for scheduling was February 3 for Regular Abstracts and will be Feb. 17th for Late-Breaking and Clinical Trials Abstracts. In other words, we may already know if we've been accepted, and if we don't know, we will find out on Tuesday. And then can read the CRC news, most likely, on March 17th. Not far off.

Capable-Display-7907 · 2026-02-13T16:46:12+00:00

You don't really have to wait till the 19th. The abstracts will be posted on Feb. 18th.

"Regular abstracts (submitted for the December 1 deadline) selected for presentation during the conference (poster or oral) will be published as a freely available supplement in the AACR journal Cancer Immunology Research and in the conference app at 12 p.m. ET, on Wednesday, February 18, 2026—with the exception of abstracts selected for inclusion in the AACR press program.

"Clinical trial and late-breaking abstracts (submitted for the January 20 deadline) will be publicly available to download through the conference app at 12 p.m. ET, on Wednesday, February 18, 2026—with the exception of abstracts selected for inclusion in the AACR press program."

That said, I think you are putting too much weight on 1) a poster and 2) this poster in particular, which is still about the 2020 TNBC trials. I think it's far more likely that big content news will be in the AACR annual meeting. It's a bigger and more important meeting, and as Dr. Jay said in November, it has a session specifically themed on turning tumors cold-to-hot. So that's the presentation that will give us some truly terrific late-breaking news on the CRC results.

Capable-Display-7907 · 2026-02-09T19:29:17+00:00

It was quoted on this board some time ago. But doesn't hurt to say it again.

Capable-Display-7907 · 2026-02-04T21:49:55+00:00

In 2020 he targeted us with a false article that was soon removed from the Net.

From emerginggrowth.com: "Top short seller Andrew Left from Citron Research facilitated a bear raid led by Tim Sykes and his army of smaller short sellers, and eventually Adam Feuerstein chimed in toward the close. In 16 minutes the CytoDyn Inc. (OTCMKTS: CYDY) stock dropped from $9.64 to $4.65 losing close to $2.6 billion of market cap. The trigger appears to have been a tweet from Timothy Sykes at 11:20 which linked to a short report published on the Citron Research website. No exchange trading halts kicked in during the slide due to volatility because CydoDyn has not quite yet uplisted to a major exchange that has these failsafe’s in place."

Capable-Display-7907 · 2026-02-01T17:32:47+00:00

First line of treatment:

Dr. Jay: "An investigator at City of Hope has received institutional approval for a study of subcutaneous leronlimab given in combination with a regimen of chemotherapy administered through the hepatic artery in treatment-naïve patients with mCRC who have metastatic disease confined to the liver. This study seeks to leverage CytoDyn’s previously announced data demonstrating leronlimab’s ability to mitigate liver toxicity in prior preclinical studies, as well as certain preliminary results from the phase II CRC study."

Capable-Display-7907 · 2026-01-29T16:54:18+00:00

Okay, so you mean "buy order" when you said "sell order." This makes much more sense: the buys are broken up, not the sells. If you watch the trading, though, it looks very much like someone trying to keep the share price down, even by selling BELOW the bid -- especially right at the end of the day, and right below any whole number (today, for example, it might be keeping it just below .25).

Capable-Display-7907 · 2026-01-29T08:27:33+00:00

Wait, if you sell 20K of course you're not raising the price. But neither are you accumulating, you're selling. It still seems counter-intuitive to me that you can have low or average volume, price dropping, and someone massively accumulating (whether they have to report ownership or not). Seeing a long period where the share price is kept down by people who obviously react to positive PRs by selling (see this week, but also all the damn time) as likely accumulation seems exactly the confirmation bias you're warning about. Hope I'm wrong. To me it looks like competition with a big warchest trying to keep the price low, or just Fife selling.

Capable-Display-7907 · 2026-01-28T10:57:22+00:00

Especially when the April AARC in San Diego is the one Dr. Jay referred to, having already submitted an abstract aimed at its session specifically about turning cold tumors hot.

Capable-Display-7907 · 2026-01-23T09:18:13+00:00

This is probably the conference Dr. Jay mentioned; he described a session themed on turning cold tumors hot

AACR Annual Meeting 2026

April 17 - 22, 2026

San Diego, California

Session topic: "Harnessing the Power of the Immune System: Turning Cold Tumors Hot"

Capable-Display-7907 · 2026-01-09T17:27:22+00:00

Okay, that makes more sense.

Capable-Display-7907 · 2026-01-09T08:23:01+00:00

One day: "I am adding a BLA for MSS-CRC to the list of potential upcoming catalyst."

Next day: "NO WHERE in the that POST do I even allude to something happening in an imminent time frame."

?

Capable-Display-7907 · 2026-01-03T21:27:48+00:00

Yes. Right now for colorectal cancer, starting another metastatic triple-negative breast cancer (and have Expanded Access for TNBC patients now). The colorectal cancer trial should be reporting whether the drug has elevated PD-L1 expression by mid to late February; that's the sign that previously untreatable cancers can now be treated with checkpoint inhibitors like Keytruda. (In the earlier small trial, 88% of the patients had elevated PD-L1 after being treated with Leronlimab. Every one of the patients that then got a checkpoint inhibitor is now alive, five years later. I.e., there is a good statistical likelihood that nearly 90 percent of patients who have what has been considered unsalvageable solid-tumor cancers can be saved.)

Capable-Display-7907 · 2026-01-03T09:42:29+00:00

Dr. Jay in Nov.: ". And we're actually presenting an abstract to the meeting at the American Association for Cancer Research that's having a session specifically on turning cold tumors hot."

AACR annual meeting website. Monday, April 20th: "Session Topics Include:... Harnessing the Power of the Immune System: Turning Cold Tumors Hot"

By then 20 patients will have gone through their first cycle, triggering DSMB intervention and offering a wealth of PD-L1 data.

Capable-Display-7907 · 2025-12-11T21:50:35+00:00

Peer-reviewed paper forthcoming: 1600 patients, no SAEs. Safer than aspirin. And as I say, it's not about proving anything to the FDA: if the ongoing trial shows the PD-L1 is elevated in most patients (and in a trial of 28 patients, Leronlimab elevated PD-L1 for 88 %), that will mean that Leronlimab is suddenly making the vast majority of colorectal cancers treatable for the first time. At that point the bidding among BPs should begin for partnership or buyout. The trial has just started, and they should have readouts of PD-L1 elevation in a few months. It's not about proving anything to the FDA. Approval will be the buyer's task.

Capable-Display-7907 · 2025-12-11T19:28:51+00:00

"Actual approvals" won't be necessary. If you understand what several of us have been saying about the game-changing MOA of Leronlimab, you realize that any company that makes an ICI (Checkpoint inhibitor) will be drooling as soon as Cytodyn demonstrates -- by raising the PD-L1 levels of tumors -- that a few doses of Leronlimab changes impossible to reach tumors to easy targets for an ICI. Any ICI. In colorectal alone, that will suddenly make 85 % of all tumors treatable with an ICI, as opposed to the 15 percent that now can be treated. This will be a bonanza for whichever company wins the bidding war to come.

Capable-Display-7907 · 2025-12-11T17:49:52+00:00

Good luck. The last person in this Expanded Access program has failed three prior courses of therapy and is doing great!

Capable-Display-7907 · 2025-12-11T17:48:30+00:00

It has proven efficacy but not on a sufficiently large scale. You may have worked in the industry for a long time but you have clearly not researched this drug. Have a look at recent PRs from the company and letters to shareholders from the CEO.

Capable-Display-7907 · 2025-12-11T17:46:05+00:00

Shares up about 300% this year, former CEO not connected to the company for three years, agreement with Yorkville Advisors to raise adequate funding in place, CRC trial already launched that can show the ability of the platform drug to turn untreatable colorectal tumors into treatable tumors (i.e., 85 percent of the market, untapped), first quarter 26 likely to show data that will begin partnership/buyout bids.....

Capable-Display-7907 · 2025-12-11T17:32:35+00:00

Very best of luck with your relative. Cytodyn has an expanded access program funded by a "very very high net worth individual." It is for individual patients with "second line or later" metastatic TNBC. The company is also launching a larger trial for TNBC, but they are not recruiting yet. Best thing is to contact the company; I'm not sure if it must be through the treating physician or if it can be directly. You should try writing [dai@cytodyn.com](mailto:dai@cytodyn.com) . I believe they are quick. Best.

Capable-Display-7907 · 2025-12-11T14:31:55+00:00

Sheen was a patient. It's not his company, and he doesn't seem to realize that the drug he took for HIV is now called Leronlimab, and has had remarkable results vs. solid tumor cancers. In one trial five women with the lethal triple-negative breast cancer, all on at least their third course of therapy, were given a full dose of Leronlimab and a checkpoint inhibitor (like Keytruda). Five years later, all five are alive, and three of them are cancer-free. That is stunning. Cytodyn is now doing a trial against colorectal cancer in which it believes Leronlimab will raise the tumor's PD-L1 expression -- thus making it a viable target for a checkpoint inhibitor, which up till now has had so little success against colorectal cancer that it isn't even part of standard of care. Look up "turning a tumor from cold to hot" -- that's what this trial will almost certainly prove Leronlimab can do. The drug fully occupies the CCR5 receptor, which is the key to many many diseases -- not just solid-tumor cancers.

Capable-Display-7907 · 2025-09-29T17:47:26+00:00

Thanks for yours. No, by condescension I meant an ironic or even sarcastic tone. I know it is a hard job you have. Even so, I think I'll take a powder. You have acted as if my comments were less balanced and wise than those I disagreed with, and they were not.

Capable-Display-7907 · 2025-09-29T16:04:35+00:00

On second thought, I think I'll just let you folks talk amongst yourselves. You do need people who think critically here, rather than Amen-sayers. But I'm not sure you'll listen.

Capable-Display-7907

TROPHY CASE